Compare BridgeBio Pharma Inc (BBIO) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Alliant Energy Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.63 (market cap $16.36B), while Alliant Energy Corporation trades at $70.06 (market cap $17.78B). The key difference: BridgeBio Pharma Inc and Alliant Energy Corporation are close in size by market cap, and Alliant Energy Corporation pays a 3.12% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LNT | |
|---|---|---|
Market Cap | $16.36B | $17.78B |
Sector | Health | Utilities |
52-Week High | $90.17 | $78.03 |
52-Week Low | $47.29 | $63.62 |
Enterprise Value | $18.14B | $29.88B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
Alliant Energy (LNT) trades at $68.21, down 1.67% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.65, beating estimates, and reaffirmed full-year guidance. Revenue grew to $4.36B in 2025, with net income margin at 18.45%. Analyst consensus is a Buy with a $77.67 price target, indicating potential upside. Recent news highlights institutional activity, including Assenagon Asset Management increasing its stake by 339.9% as of August 12, 2026.
LNT presents a stable investment opportunity with consistent earnings beats and a dividend yield, but faces risks from rising debt levels and bearish technical trends. The stock's valuation metrics, including a P/E of 21.7, are reasonable for the utilities sector. Upside is supported by analyst targets, while headwinds include higher interest costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
